Page last updated: 2024-09-03

gefitinib and Epithelial Ovarian Cancer

gefitinib has been researched along with Epithelial Ovarian Cancer in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	2 (66.67)	2.80

Authors

Authors	Studies
Hu, M; Li, J; Li, M; Li, Z; Wang, Y; Xi, M; Xia, Z; Zheng, D; Zheng, X	1
Chang, SJ; Chuang, YJ; Lai, ZY; Tsai, KY	1
Gui, T; Shen, K	1

Reviews

1 review(s) available for gefitinib and Epithelial Ovarian Cancer

Article	Year
The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. Cancer epidemiology, 2012, Volume: 36, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cetuximab; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Molecular Targeted Therapy; Mutation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Panitumumab; Protein-Tyrosine Kinases; Quinazolines	2012

Article

Year

The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.

Cancer epidemiology, 2012, Volume: 36, Issue:5

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cetuximab; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Molecular Targeted Therapy; Mutation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Panitumumab; Protein-Tyrosine Kinases; Quinazolines

2012

Other Studies

2 other study(ies) available for gefitinib and Epithelial Ovarian Cancer

Article	Year
Loss of RBPMS in ovarian cancer compromises the efficacy of EGFR inhibitor gefitinib through activating HER2/AKT/mTOR/P70S6K signaling. Biochemical and biophysical research communications, 2022, 12-31, Volume: 637 Topics: Carcinoma, Ovarian Epithelial; ErbB Receptors; Female; Gefitinib; Humans; Ovarian Neoplasms; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; RNA-Binding Proteins; TOR Serine-Threonine Kinases	2022
Gain-of-Function Mutant TP53 R248Q Overexpressed in Epithelial Ovarian Carcinoma Alters AKT-Dependent Regulation of Intercellular Trafficking in Responses to EGFR/MDM2 Inhibitor. International journal of molecular sciences, 2021, Aug-16, Volume: 22, Issue:16 Topics: Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cystadenocarcinoma, Serous; ErbB Receptors; Female; Gain of Function Mutation; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Signal Transduction; Tryptamines; Tumor Suppressor Protein p53; Up-Regulation	2021

Article

Year

Loss of RBPMS in ovarian cancer compromises the efficacy of EGFR inhibitor gefitinib through activating HER2/AKT/mTOR/P70S6K signaling.

Biochemical and biophysical research communications, 2022, 12-31, Volume: 637

Topics: Carcinoma, Ovarian Epithelial; ErbB Receptors; Female; Gefitinib; Humans; Ovarian Neoplasms; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; RNA-Binding Proteins; TOR Serine-Threonine Kinases

2022

Gain-of-Function Mutant TP53 R248Q Overexpressed in Epithelial Ovarian Carcinoma Alters AKT-Dependent Regulation of Intercellular Trafficking in Responses to EGFR/MDM2 Inhibitor.

International journal of molecular sciences, 2021, Aug-16, Volume: 22, Issue:16

Topics: Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cystadenocarcinoma, Serous; ErbB Receptors; Female; Gain of Function Mutation; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Signal Transduction; Tryptamines; Tumor Suppressor Protein p53; Up-Regulation

2021